Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 17.50
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 1.50 (8.571%)
Open: 18.25
High: 18.25
Low: 17.50
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SlimBiome® Approved by Health Canada

25 Oct 2021 07:00

RNS Number : 0118Q
OptiBiotix Health PLC
25 October 2021
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

SlimBiome® Approved by Health Canada

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds that modulate the microbiome to tackle metabolic syndrome, systemic low grade inflammation, obesity and diabetes, cardiovascular disease and high cholesterol, announces that SlimBiome® has received approval for use as a licensed product for weight management by Health Canada, a Canadian federal institution responsible for helping Canadians maintain and improve their health.

 

In Canada, every supplement must be approved and authorised by Health Canada, as a licensed Natural Health Product (NHP) and receive a National Product Number (NPN). The NPN is displayed on the product label and is confirmation that a product has been assessed and found to be safe and effective with approved health claims. As part of the approval process Health Canada have validated the scientific and clinical data on SlimBiome® and determined the following health and nutrition claims can be made: -

 

· Helps to lower cholesterol levels by reducing cholesterol absorption from the gastrointestinal tract

· Helps to maintain normal blood glucose levels and supports a healthy glucose metabolism

· Helps to prevent chromium deficiency and maintains the body's ability to metabolize nutrients

· Complementary to a healthy lifestyle with a calorie-reduced diet and regular physical activity for individuals involved in weight management

· Helps to support a feeling of fullness

· Is a source of fiber and prebiotics

 

Health Canada is seen as one of the world's leading authorities on regulating functional ingredients and supplements ensuring products are safe and marketed with approved health and nutrition claims. Health Canada approval is internationally recognised as a mark of a product quality, safety, and effectiveness and can lead to shortened product registration procedures in other international markets.

 

SlimBiome® is a patented weight management ingredient supported by independent human clinical studies (Keleszade et al, 2020) which show it reduces hunger, cravings for sweet and savoury foods, and fat intake. In addition to clinical studies, independent consumer surveys have shown that customers who used SlimBiome® in combination with a calorie restricted diet lose on average 2-3lbs (1-1.5kg) per week, experience a relief from feeling hungry and have fewer cravings for food, leading to easier and more sustainable dieting.

 

SlimBiome® has achieved three major industry awards: European Weight Management Ingredient of the Year (NutraIngredients 2018), Asia Weight Management Ingredient of the Year (NutraIngredients 2019), and most recently, best weight management product in the USA (Nutrition Industry Executive Award 2021).

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are pleased to achieve product approval for SlimBiome® by one of the toughest regulatory bodies in the world. This is a significant achievement and brings further international recognition to SlimBiome® as a scientifically backed and proven weight management ingredient. It underlines the value of the investment we made in a number of human clinical studies showing SlimBiome's® effectiveness and the creation of a large IP portfolio. SlimBiome® has won three major industry awards across all regions, obtained CE marked medical device registration in Europe, and now is a weight management product with approved health and nutrition claims by Health Canada. This opens up the Canadian and North American market for new sales opportunities and provides further validation of our product in international markets."

 

Carla Fabian, Sales Director of Agropur (Optibiotix's partner in North America) commented: "Health Canada approval and recognition with an NPN number is exciting news as this allows Agropur to safely manufacture, distribute, and sell SlimBiome in the Canadian marketplace. The registration is recognised by consumers, brand owners, retailers, and professional health care workers like pharmacists and dietitians. Everyone can be assured that SlimBiome® is safe, of high quality, and can amongst others help deliver benefits with respect to cholesterol reduction, maintaining blood glucose levels and compliment a healthy lifestyle. We, along with Optibiotix, look forward to partnering with brand owners who are looking to add proven science-based weight management functionality to existing products or to assist with new product development utilising our extensive innovation resources."

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAFLFIRITLFFIL
Date   Source Headline
28th Jul 20162:30 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSCompletion of pilot launch and creation of JV
14th Jul 20167:00 amRNSNew patent filing
5th Jul 20167:00 amRNSStrategy update
4th Jul 20163:36 pmRNSHolding(s) in Company
30th Jun 20163:06 pmRNSExercise of Warrants and Issue of Equity
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
2nd Jun 201612:18 pmRNSExercise of Warrants and Issue of Equity
19th May 20167:00 amRNSNew patent filing
10th May 201612:39 pmRNSResult of AGM
20th Apr 201612:18 pmRNSExercise of Warrants and Issue of Equity
14th Apr 20167:00 amRNSFinal Results
7th Apr 20167:00 amRNSResults of cholesterol human volunteer study
5th Apr 20167:00 amRNSJoint development agreement signed with Royal DSM
24th Mar 20167:00 amRNSExercise of Warrants and Issue of Equity
23rd Mar 20167:00 amRNSNotice of Results
22nd Mar 20167:00 amRNSSecond contract signed for Sweetbiotix
17th Mar 20167:00 amRNSJV agreement with the University of Manchester
26th Feb 201610:57 amRNSExercise of Warrants and Issue of Equity
19th Feb 201610:12 amRNSExercise of Warrants and Issue of Equity
12th Feb 20169:49 amRNSExercise of Warrants and Issue of Equity
5th Feb 20167:00 amRNSPlacing
28th Jan 201612:51 pmRNSInvestor presentation - change of venue
26th Jan 20167:00 amRNSExercise of Warrants and Issue of Equity
20th Jan 20167:00 amRNSInvestor presentation
19th Jan 20167:00 amRNSScientific Advisory Group appointment
13th Jan 20167:00 amRNSCommercial agreement signed with KSF Acquisition
21st Dec 20157:00 amRNSCompletion of Placing, Total Voting Rights
11th Dec 20151:30 pmRNSCorrection: Exercise of Warrants & Issue of Equity
11th Dec 201511:30 amRNSExercise of Warrants and Issue of Equity
7th Dec 20157:00 amRNSPlacing and Directors' Dealings
24th Nov 20157:00 amRNSDirectorate Change
20th Nov 20157:00 amRNSDevelopment agreement signed with CSL
16th Nov 201510:49 amRNSExercise of Warrants and Issue of Equity
5th Nov 20154:40 pmRNSSecond Price Monitoring Extn
5th Nov 20154:35 pmRNSPrice Monitoring Extension
3rd Nov 20157:00 amRNSNew patent filings
7th Oct 201512:30 pmRNSHolding(s) in Company
7th Oct 20157:00 amRNSNew microbial strain registrations
29th Sep 20157:00 amRNSCompletion of human studies
18th Sep 20154:18 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20157:00 amRNSHalf Yearly Report
11th Aug 201512:08 pmRNSResult of AGM
28th Jul 20157:00 amRNSCompletion of human studies
9th Jul 20157:00 amRNSContract signed with Instituto de Química Orgánica
23rd Jun 20155:00 pmRNSHolding(s) in Company
17th Jun 20154:59 pmRNSExercise of Warrants and Issue of Equity
12th Jun 20152:05 pmRNSHolding(s) in Company
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.